Gregory Sorensen, MD, of the MGH Radiology Division and Martinos Center for Biomedical Imaging, co-senior writer of the report. ‘The actual fact that anti-VEGF agents seem to provide obvious benefits in some glioblastoma patients adds to the urgency of understanding the mechanisms that underlie these clinical improvements. We need to learn to tailor our remedies to benefit a lot more patients.’ The existing study was designed to clarify whether cediranib’s clinical effects primarily resulted from reduction of edema, which has significant implications within the brain, or from a primary anti-tumor effect.Mr. Malek joins BioLineRx from Sanofi, where he offered as Director of Oncology – SERVICES and Business Advancement. Related StoriesAMSBIO launches Mimetix 3D cell tradition scaffolds for medication discovery, oncology researchLilly, ImaginAb partner to review potential novel T-cell-structured immuno-oncology therapiesNew UCL research highlights genes connected with schizophrenia and obesitySummary of economic results for the 3rd quarter and 1st nine months of 2011: Revenues for the 90 days and nine weeks ended September 30, 2010 reflected an upfront payment of $30.0 million received regarding the the out-licensing contract signed with Cypress Bioscience this year 2010 according of BL-1020.